Overview
Announcements

Ordinary Rebalance | Solactive China Healthcare Disruption Index | Effective Date 1st March 2024

Solactive China Healthcare Disruption Index:

In the ordinary rebalance, effective open 01.03.2024 the following index composition was implemented:

3SBIO INC 0.1653 %
AKESO INC 7.9408 %
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD 7.6301 %
ALPHAMAB ONCOLOGY 0.0635 %
CANSINO BIOLOGICS INC 1.7468 %
CHINA MEDICAL SYSTEM HOLDINGS LTD 0.4135 %
CHINA RESOURCES PHARMACEUTICAL 7.7087 %
CSPC PHARMACEUTICAL GROUP LTD 7.2519 %
GENSCRIPT BIOTECH CORP 8.2996 %
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD 0.4617 %
HANSOH PHARMACEUTICAL GROUP CO 7.5579 %
HUTCHMED CHINA LTD 0.2765 %
INNOVENT BIOLOGICS INC 8.0588 %
JD HEALTH INTERNATIONAL INC 0.459 %
KEYMED BIOSCIENCES INC 2.3673 %
LIVZON PHARMACEUTICAL GROUP INC 0.4654 %
LUYE PHARMA GROUP LTD 0.1426 %
PHARMARON BEIJING CO LTD-H 0.5174 %
REMEGEN CO LTD-H 0.3714 %
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD 7.9513 %
SHANGHAI JUNSHI BIOSCIENCES CO LTD 0.4201 %
SHANGHAI MICROPORT MEDBOT GR 3.4155 %
SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H 0.4886 %
SIMCERE PHARMACEUTICAL GROUP 0.1906 %
SINO BIOPHARMACEUTICAL LTD ORD 7.5309 %
SKB BIO-B ORD H 0.1798 %
WUXI APPTEC CO LTD 8.8518 %
WUXI BIOLOGICS CAYMAN INC 8.7641 %
YICHANG HEC CHANGJIANG PHA-H 0.0874 %
ZAI LAB LTD 0.2217 %